Psyence Biomedical Sets February 2 Effective Date for 1-for-6.25 Reverse Stock Split

The latest update is out from Psyence Biomedical ( (PBM) ).

On January 28, 2026, Psyence Biomedical announced that its previously approved 1-for-6.25 reverse stock split of its common shares will become effective at the market open on February 2, 2026, after an earlier plan to implement the change on January 20, 2026 was delayed. The move follows shareholder authorization in April 2025 for a potential consolidation of up to 1-for-50 and a prior 1-for-7.97 reverse split executed on May 5, 2025, reflecting the company’s ongoing efforts to manage its capital structure and support continued compliance with Nasdaq listing requirements. As of January 21, 2026, Psyence Biomedical had 6,388,604 common shares outstanding, which will be reduced to approximately 1,022,177 shares post-consolidation, with proportional adjustments to warrants and other equity instruments; the consolidation will not materially change shareholders’ ownership percentages aside from minor rounding effects on fractional shares, and the stock will continue trading under the PBM ticker with a new CUSIP number.

More about Psyence Biomedical

Psyence Biomedical Ltd. (Nasdaq: PBM) is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived (non-synthetic) psilocybin and ibogaine-based medicines. It positions itself as one of the few multi-asset players in this niche and the first life sciences biotechnology company focused on nature-derived psychedelic treatments to list on Nasdaq, targeting unmet mental health needs through evidence-based development of safe, effective, regulator-approved therapies for a broad range of mental health disorders.

Average Trading Volume: 1,514,956

Technical Sentiment Signal: Sell

Current Market Cap: $645.1K

See more data about PBM stock on TipRanks’ Stock Analysis page.